Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Trial Parameters
Brief Summary
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.
Eligibility Criteria
Inclusion Criteria: * Able to provide informed consent in English or French * Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD * Have a Full-Scale IQ ≥ 75 * Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only) * Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only) * Clinically stable (as measured by the PANSS-6, total score \<30) (psychosis patient arm only) Exclusion Criteria: * current SUD (other than CUD) * MRI contraindications * Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine * Current suicidal or homicidal ideation * Head injury requiring hospitalization or loss of consciousness \> 5 minutes * Current medical diseases that requires hospitalization or regular monitoring * Being pregnant * DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only) * Taking psychotropic medication